View in EDS HTML Full Text PDF Full Text

Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma.

Saved in:
Bibliographic Details
Title: Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma.
Authors: Horwitz SM; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Feldman TA; John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, NJ, USA., Ye JC; University of Michigan, Ann Arbor, MI, USA., Khodadoust MS; Stanford University School of Medicine, Palo Alto, CA, USA., Munoz J; Banner MD Anderson Cancer Center, Gilbert, AZ, USA., Hamlin PA; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Kim YH; Stanford University School of Medicine, Palo Alto, CA, USA., Wilcox RA; University of Michigan, Ann Arbor, MI, USA., Patel MR; Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA., Coffey G; Alexion, AstraZeneca Rare Disease, Boston, MA, USA., Innes A; Alexion, AstraZeneca Rare Disease, Boston, MA, USA., Betz A; Alexion, AstraZeneca Rare Disease, Boston, MA, USA., Holland J; Alexion, AstraZeneca Rare Disease, Boston, MA, USA., Guzman CB; Alexion, AstraZeneca Rare Disease, Boston, MA, USA., Smith SM; University of Chicago Medicine, Chicago, IL, USA.
Source: Leukemia & lymphoma [Leuk Lymphoma] 2025 Jun; Vol. 66 (6), pp. 1100-1110. Date of Electronic Publication: 2025 Feb 08.
Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study
Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39921522
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Horwitz+SM%22">Horwitz SM</searchLink>; Memorial Sloan Kettering Cancer Center, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Feldman+TA%22">Feldman TA</searchLink>; John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Ye+JC%22">Ye JC</searchLink>; University of Michigan, Ann Arbor, MI, USA.<br /><searchLink fieldCode="AU" term="%22Khodadoust+MS%22">Khodadoust MS</searchLink>; Stanford University School of Medicine, Palo Alto, CA, USA.<br /><searchLink fieldCode="AU" term="%22Munoz+J%22">Munoz J</searchLink>; Banner MD Anderson Cancer Center, Gilbert, AZ, USA.<br /><searchLink fieldCode="AU" term="%22Hamlin+PA%22">Hamlin PA</searchLink>; Memorial Sloan Kettering Cancer Center, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Kim+YH%22">Kim YH</searchLink>; Stanford University School of Medicine, Palo Alto, CA, USA.<br /><searchLink fieldCode="AU" term="%22Wilcox+RA%22">Wilcox RA</searchLink>; University of Michigan, Ann Arbor, MI, USA.<br /><searchLink fieldCode="AU" term="%22Patel+MR%22">Patel MR</searchLink>; Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA.<br /><searchLink fieldCode="AU" term="%22Coffey+G%22">Coffey G</searchLink>; Alexion, AstraZeneca Rare Disease, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Innes+A%22">Innes A</searchLink>; Alexion, AstraZeneca Rare Disease, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Betz+A%22">Betz A</searchLink>; Alexion, AstraZeneca Rare Disease, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Holland+J%22">Holland J</searchLink>; Alexion, AstraZeneca Rare Disease, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Guzman+CB%22">Guzman CB</searchLink>; Alexion, AstraZeneca Rare Disease, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Smith+SM%22">Smith SM</searchLink>; University of Chicago Medicine, Chicago, IL, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229007422%22">Leukemia & lymphoma</searchLink> [Leuk Lymphoma] 2025 Jun; Vol. 66 (6), pp. 1100-1110. <i>Date of Electronic Publication: </i>2025 Feb 08.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9007422 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1029-2403 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210268022%22">10268022 </searchLink><i>NLM ISO Abbreviation: </i>Leuk Lymphoma <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39921522
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/10428194.2025.2455489
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1100
    Titles:
      – TitleFull: Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Horwitz SM
      – PersonEntity:
          Name:
            NameFull: Feldman TA
      – PersonEntity:
          Name:
            NameFull: Ye JC
      – PersonEntity:
          Name:
            NameFull: Khodadoust MS
      – PersonEntity:
          Name:
            NameFull: Munoz J
      – PersonEntity:
          Name:
            NameFull: Hamlin PA
      – PersonEntity:
          Name:
            NameFull: Kim YH
      – PersonEntity:
          Name:
            NameFull: Wilcox RA
      – PersonEntity:
          Name:
            NameFull: Patel MR
      – PersonEntity:
          Name:
            NameFull: Coffey G
      – PersonEntity:
          Name:
            NameFull: Innes A
      – PersonEntity:
          Name:
            NameFull: Betz A
      – PersonEntity:
          Name:
            NameFull: Holland J
      – PersonEntity:
          Name:
            NameFull: Guzman CB
      – PersonEntity:
          Name:
            NameFull: Smith SM
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: 2025 Jun
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1029-2403
          Numbering:
            – Type: volume
              Value: 66
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Leukemia & lymphoma
              Type: main
ResultId 1